Regulation of vascular smooth muscle cell growth: targeting the final common pathway.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Transcriptional and post-transcriptional regulation of cGMP-dependent protein kinase (PKG-I): pathophysiological significance.Cardiovascular research · 2013
   Review
2. Dahuang zhechong pill containing serum inhibited platelet-derived growth factor-stimulated vascular smooth muscle cells proliferation by inducing G1 arrest partly via suppressing protein kinase C α-extracellular regulated kinase 1/2 signaling pathway.Chinese journal of integrative medicine · 2012
   Article
3. NR4A Orphan Nuclear Receptors in Cardiovascular Biology.Drug discovery today. Disease mechanisms · 2009
   Article

Corrections and comments

• Comment on
  Grb2 is required for the development of neointima in response to vascular injury.2003

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as